ATE298765T1 - Beta-amyloid peptidaggregation regulierende peptide mit d-aminosäuren - Google Patents

Beta-amyloid peptidaggregation regulierende peptide mit d-aminosäuren

Info

Publication number: ATE298765T1
Authority: AT; Austria
Prior art keywords: beta; peptide; amyloid peptide; compounds; amino
Prior art date: 1996-08-27

Application number

AT97940663T

Other languages

English (en)

Inventor

Mark A Findeis

Malcolm L Gefter

Gary Musso

Ethan R Signer

James Wakefield

Susan Molineaux

Joseph Chin

Jung-Ja Lee

Michael Kelley

Sonja Komar-Panicucci

Christopher C Arico-Muendel

Kathryn Phillips

Neil J Hayward

Original Assignee

Praecis Pharm Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-08-27

Filing date

1997-08-27

Publication date

2005-07-15

1996-08-27 Priority claimed from US08/703,675 external-priority patent/US6303567B1/en

1997-08-27 Application filed by Praecis Pharm Inc filed Critical Praecis Pharm Inc

2005-07-15 Application granted granted Critical

2005-07-15 Publication of ATE298765T1 publication Critical patent/ATE298765T1/de

Links

108090000765 processed proteins & peptides Proteins 0.000 title abstract 5
150000008574 D-amino acids Chemical class 0.000 title abstract 4
DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 title abstract 4
230000006919 peptide aggregation Effects 0.000 title abstract 2
102000004196 processed proteins & peptides Human genes 0.000 title 1
230000001105 regulatory effect Effects 0.000 title 1
125000003368 amide group Chemical group 0.000 abstract 3
150000001875 compounds Chemical class 0.000 abstract 3
125000000217 alkyl group Chemical group 0.000 abstract 2
ROHFNLRQFUQHCH-RXMQYKEDSA-N D-leucine Chemical compound CC(C)C[C@@H](N)C(O)=O ROHFNLRQFUQHCH-RXMQYKEDSA-N 0.000 abstract 1
229930182819 D-leucine Natural products 0.000 abstract 1
COLNVLDHVKWLRT-MRVPVSSYSA-N D-phenylalanine Chemical compound OC(=O)[C@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-MRVPVSSYSA-N 0.000 abstract 1
229930182832 D-phenylalanine Natural products 0.000 abstract 1
125000003118 aryl group Chemical group 0.000 abstract 1
210000004899 c-terminal region Anatomy 0.000 abstract 1
125000004122 cyclic group Chemical group 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
125000000623 heterocyclic group Chemical group 0.000 abstract 1
125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
125000003367 polycyclic group Chemical group 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
General Health & Medical Sciences (AREA)
Neurosurgery (AREA)
Animal Behavior & Ethology (AREA)
Gastroenterology & Hepatology (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Psychiatry (AREA)
Hospice & Palliative Care (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Toxicology (AREA)
Zoology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Investigating Or Analysing Biological Materials (AREA)

AT97940663T 1996-08-27 1997-08-27 Beta-amyloid peptidaggregation regulierende peptide mit d-aminosäuren ATE298765T1 (de)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US08/703,675 US6303567B1 (en)	1995-03-14	1996-08-27	Modulators of β-amyloid peptide aggregation comprising D-amino acids
US89734297A	1997-07-21	1997-07-21
PCT/US1997/015166 WO1998008868A1 (en)	1996-08-27	1997-08-27	MODULATORS OF β-AMYLOID PEPTIDE AGGREGATION COMPRISING D-AMINO ACIDS

Publications (1)

Publication Number	Publication Date
ATE298765T1 true ATE298765T1 (de)	2005-07-15

Family

ID=27107183

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT97940663T ATE298765T1 (de)	1996-08-27	1997-08-27	Beta-amyloid peptidaggregation regulierende peptide mit d-aminosäuren

Country Status (11)

Country	Link
EP (2)	EP1586584A1 (de)
JP (1)	JP2001500852A (de)
AT (1)	ATE298765T1 (de)
AU (1)	AU741199B2 (de)
CA (1)	CA2262453A1 (de)
DE (1)	DE69733655T2 (de)
DK (1)	DK0929574T3 (de)
ES (1)	ES2245003T3 (de)
HK (1)	HK1021741A1 (de)
PT (1)	PT929574E (de)
WO (1)	WO1998008868A1 (de)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5985242A (en) *	1995-10-27	1999-11-16	Praecis Pharmaceuticals, Inc.	Modulators of β-amyloid peptide aggregation comprising D-amino acids
US6277826B1 (en)	1996-08-27	2001-08-21	Praecis Pharmaceuticals, Inc.	Modulators of β-amyloid peptide aggregation comprising D-amino acids
WO1997021728A1 (en)	1995-12-12	1997-06-19	Karolinska Innovations Ab	PEPTIDE BINDING THE KLVFF-SEQUENCE OF AMYLOID $g(b)
US6172043B1 (en) *	1997-01-10	2001-01-09	Massachusetts Institute Of Technology	Treatments for neurotoxicity in Alzheimer's disease caused by β amyloid peptides
US7179892B2 (en)	2000-12-06	2007-02-20	Neuralab Limited	Humanized antibodies that recognize beta amyloid peptide
US6905686B1 (en)	1997-12-02	2005-06-14	Neuralab Limited	Active immunization for treatment of alzheimer's disease
US7588766B1 (en)	2000-05-26	2009-09-15	Elan Pharma International Limited	Treatment of amyloidogenic disease
TWI239847B (en)	1997-12-02	2005-09-21	Elan Pharm Inc	N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US6761888B1 (en)	2000-05-26	2004-07-13	Neuralab Limited	Passive immunization treatment of Alzheimer's disease
US7964192B1 (en)	1997-12-02	2011-06-21	Janssen Alzheimer Immunotherapy	Prevention and treatment of amyloidgenic disease
US20080050367A1 (en)	1998-04-07	2008-02-28	Guriq Basi	Humanized antibodies that recognize beta amyloid peptide
US7790856B2 (en)	1998-04-07	2010-09-07	Janssen Alzheimer Immunotherapy	Humanized antibodies that recognize beta amyloid peptide
US6913745B1 (en)	1997-12-02	2005-07-05	Neuralab Limited	Passive immunization of Alzheimer's disease
ATE366259T1 (de) *	1999-03-04	2007-07-15	Praecis Pharm Inc	Beta-amyloid-peptidaggregation regulierende peptide mit d-aminosäuren
EP1870419A3 (de) *	1999-03-04	2008-01-02	Praecis Pharmaceuticals Incorporated	Modulatoren der Beta-Amyloid-Peptid-Aggregation mit D-Aminosäuren
US7060670B1 (en)	1999-05-05	2006-06-13	Neurochem (International) Limited	Stereoselective antifibrillogenic peptides and peptidomimetics thereof
ATE384077T1 (de) *	1999-05-05	2008-02-15	Neurochem Int Ltd	Stereoselektive antifibrillogene peptide
AU781044B2 (en) *	1999-11-05	2005-05-05	Axonyx, Inc.	Peptide analogs and mimetics suitable for in vivo use in the treatment of diseases associated with abnormal protein folding into amyloid, amyloid-like deposits or beta-sheet rich pathological precursor thereof
KR20020073341A (ko) *	1999-11-29	2002-09-23	뉴로켐, 인크.	알츠하이머 및 아밀로이드 관련 질병의 예방 및 치료용 백신
US20020142950A1 (en) *	2000-02-11	2002-10-03	Hayward Neil J.	Methods for enhancing the bioavailability of a drug
GB2363983A (en)	2000-06-29	2002-01-16	Hunter Fleming Ltd	Protection against neuronal damage using 7-hydroxyepiandrosterone
GB2363984A (en) *	2000-06-29	2002-01-16	Hunter Fleming Ltd	Protection against neuronal damage using 3-hydroxy-7 -hydroxy steroids and 3-oxo-7 -hydroxy steroids
US7067550B2 (en)	2000-11-03	2006-06-27	Massachusetts Institute Of Technology	Treatments for neurotoxicity in Alzheimer's Disease
WO2002035987A2 (en)	2000-11-03	2002-05-10	Massachusetts Institute Of Technology	METHODS FOR IDENTIFYING TREATMENTS FOR NEUROTOXICITY IN ALZHEIMER'S DISEASE CAUSED BY β-AMYLOID PEPTIDES
TWI255272B (en)	2000-12-06	2006-05-21	Guriq Basi	Humanized antibodies that recognize beta amyloid peptide
US7700751B2 (en)	2000-12-06	2010-04-20	Janssen Alzheimer Immunotherapy	Humanized antibodies that recognize β-amyloid peptide
JP5057628B2 (ja) *	2001-01-17	2012-10-24	ツィンメル・ロベール・アッシュ	ポリペプチド・ドラッグ物質および他の難吸収性活性成分を含む組成物の経口および非経口投与後の薬理活性を強化させる組成物および方法
JP4354180B2 (ja) *	2001-12-26	2009-10-28	武田薬品工業株式会社	軽度認知障害治療剤
US20040052928A1 (en)	2002-09-06	2004-03-18	Ehud Gazit	Peptides and methods using same for diagnosing and treating amyloid-associated diseases
KR101011657B1 (ko)	2002-03-01	2011-01-28	다케다 야쿠힌 고교 가부시키가이샤	항우울제
MY139983A (en)	2002-03-12	2009-11-30	Janssen Alzheimer Immunotherap	Humanized antibodies that recognize beta amyloid peptide
US6846640B2 (en)	2002-04-30	2005-01-25	Pharmacia & Upjohn Company	Time-resolved fluorescence assay for the detection of multimeric forms of A-beta 1-40
PE20050627A1 (es)	2003-05-30	2005-08-10	Wyeth Corp	Anticuerpos humanizados que reconocen el peptido beta amiloideo
CA2530927A1 (en)	2003-06-30	2005-01-06	Tel Aviv University Future Technology Development L.P.	Peptides antibodies directed thereagainst and methods using same for diagnosing and treating amyloid-associated diseases
ES2434732T3 (es)	2004-12-15	2013-12-17	Janssen Alzheimer Immunotherapy	Anticuerpos para beta-amiloide humanizados para su uso en mejorar la cognición
ES2396555T3 (es)	2004-12-15	2013-02-22	Janssen Alzheimer Immunotherapy	Anticuerpos que reconocen péptido beta amiloide
US7812025B2 (en)	2005-08-12	2010-10-12	Takeda Pharmaceutical Company Limited	Brain/neuronal cell-protecting agent and therapeutic agent for sleep disorder
US8784810B2 (en)	2006-04-18	2014-07-22	Janssen Alzheimer Immunotherapy	Treatment of amyloidogenic diseases
WO2008050133A2 (en) *	2006-10-27	2008-05-02	Zapaloid Limited	Inhibition of beta-amyloid aggregation
US8906859B2 (en)	2006-11-10	2014-12-09	Cera Therapeutics, Inc.	Uses of kappa opioid synthetic peptide amides
US8236766B2 (en)	2006-11-10	2012-08-07	Cara Therapeutics, Inc.	Uses of synthetic peptide amides
CA2667155C (en)	2006-11-10	2016-05-10	Cara Therapeutics, Inc.	Synthetic peptide amides
US7713937B2 (en)	2006-11-10	2010-05-11	Cara Therapeutics, Inc.	Synthetic peptide amides and dimeric forms thereof
US7842662B2 (en)	2006-11-10	2010-11-30	Cara Therapeutics, Inc.	Synthetic peptide amide dimers
WO2008099210A2 (en)	2007-02-12	2008-08-21	Merck & Co., Inc.	Piperazine derivatives for treatment of ad and related conditions
US8003097B2 (en)	2007-04-18	2011-08-23	Janssen Alzheimer Immunotherapy	Treatment of cerebral amyloid angiopathy
PT2182983E (pt)	2007-07-27	2014-09-01	Janssen Alzheimer Immunotherap	Tratamento de doenças amiloidogénicas com anticorpos anti-abeta humanizados
JO3076B1 (ar)	2007-10-17	2017-03-15	Janssen Alzheimer Immunotherap	نظم العلاج المناعي المعتمد على حالة apoe
US9067981B1 (en)	2008-10-30	2015-06-30	Janssen Sciences Ireland Uc	Hybrid amyloid-beta antibodies
PE20120357A1 (es)	2009-03-10	2012-05-03	Takeda Pharmaceutical	Derivados de benzofurano
BR112013008420A2 (pt)	2010-10-07	2016-06-28	Takeda Pharmaceutical	composto, medicamento, e, uso do composito
JP5911503B2 (ja)	2010-11-15	2016-04-27	ラモット・アット・テル・アビブ・ユニバーシテイ・リミテッドＲａｍｏｔＡｔＴｅｌＡｖｉｖＵｎｉｖｅｒｓｉｔｙＬｔｄ．	アミロイド線維形成関連状態を処置するためのジペプチドアナログ
CA2851087C (en)	2011-10-07	2019-09-24	Takeda Pharmaceutical Company Limited	1-arylcarbonyl-4-oxy-piperidine compounds useful for the treatment of neurodegenerative diseases
WO2014061676A1 (ja)	2012-10-16	2014-04-24	武田薬品工業株式会社	複素環化合物
GEP201706756B (en)	2012-12-11	2017-10-25	Takeda Pharmaceuticals Co	Heterocyclic compound
JP6272833B2 (ja)	2013-04-04	2018-01-31	武田薬品工業株式会社	複素環化合物
JP6272832B2 (ja)	2013-04-04	2018-01-31	武田薬品工業株式会社	複素環化合物
US9963443B2 (en)	2014-06-09	2018-05-08	Takeda Pharmaceutical Company Limited	Radiolabeled compounds
SI3411358T1 (sl)	2016-02-04	2022-04-29	Takeda Pharmaceutical Company Limited	Substituirana piperidinska spojina in njena uporaba
WO2018164191A1 (ja)	2017-03-08	2018-09-13	武田薬品工業株式会社	置換ピロリジン化合物およびその用途
ES2973672T3 (es)	2017-07-28	2024-06-21	Takeda Pharmaceuticals Co	Compuesto heterocíclico
KR102582785B1 (ko)	2017-08-03	2023-09-26	다케다 야쿠힌 고교 가부시키가이샤	헤테로시클릭 화합물 및 이의 용도
AU2019241765B2 (en)	2018-03-28	2022-07-07	Takeda Pharmaceutical Company Limited	Heterocyclic compound and use thereof
WO2020004536A1 (ja)	2018-06-29	2020-01-02	武田薬品工業株式会社	複素環化合物およびその用途
US20220089525A1 (en)	2019-01-24	2022-03-24	Takeda Pharmaceutical Company Limited	Heterocyclic compound and use thereof
TWI855081B (zh)	2019-05-24	2024-09-11	美商賽吉醫療公司	化合物、組合物及使用方法
CN114980892A (zh)	2019-09-13	2022-08-30	武田药品工业株式会社	用于治疗发作性睡病的tak-925
KR20220062361A (ko)	2019-09-13	2022-05-16	다케다 야쿠힌 고교 가부시키가이샤	과도한 졸림의 치료를 위한 오렉신 2 수용체 효능제의 용도
JP2021050161A (ja)	2019-09-25	2021-04-01	武田薬品工業株式会社	複素環化合物及びその用途
JP2021080177A (ja)	2019-11-14	2021-05-27	武田薬品工業株式会社	複素環化合物及びその用途
JP2021183587A (ja)	2020-05-22	2021-12-02	武田薬品工業株式会社	複素環化合物
EP4251618A1 (de)	2020-11-25	2023-10-04	Sage Therapeutics, Inc.	4-fluor-(4-(4-benzyl)piperidin-1-yl)(2-(pyrimidin-4-yl)pyridin-3-yl)methanonderivate und ähnliche verbindungen als cyp46a1-inhibitoren zur behandlung neurodegenerativer erkrankungen
WO2022190060A1 (en)	2021-03-12	2022-09-15	Takeda Pharmaceutical Company Limited	An orexin 2 receptor agonist for the treatment of an orexin-mediated disease or disorder
WO2022208478A1 (en)	2021-04-02	2022-10-06	Takeda Pharmaceutical Company Limited	Use of an orexin 2 receptor agonist for post operation recovery
WO2023090268A1 (ja)	2021-11-17	2023-05-25	武田薬品工業株式会社	細胞の製造方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5338837A (en) *	1991-12-13	1994-08-16	The Trustees Of Princeton University	Glycosylated steroid derivatives for transport across biological membranes and process for making same
WO1994019692A1 (en) *	1993-02-18	1994-09-01	The General Hospital Corporation	Alzheimer's disease therapeutics
JPH11514333A (ja) *	1995-03-14	1999-12-07	プレーシスファーマスーティカルズインコーポレイテッド	アミロイドの凝集の調節剤
WO1997021728A1 (en) *	1995-12-12	1997-06-19	Karolinska Innovations Ab	PEPTIDE BINDING THE KLVFF-SEQUENCE OF AMYLOID $g(b)

1997
- 1997-08-27 AT AT97940663T patent/ATE298765T1/de not_active IP Right Cessation
- 1997-08-27 DK DK97940663T patent/DK0929574T3/da active
- 1997-08-27 PT PT97940663T patent/PT929574E/pt unknown
- 1997-08-27 ES ES97940663T patent/ES2245003T3/es not_active Expired - Lifetime
- 1997-08-27 EP EP05013789A patent/EP1586584A1/de not_active Withdrawn
- 1997-08-27 EP EP97940663A patent/EP0929574B1/de not_active Expired - Lifetime
- 1997-08-27 JP JP10511914A patent/JP2001500852A/ja not_active Ceased
- 1997-08-27 WO PCT/US1997/015166 patent/WO1998008868A1/en active IP Right Grant
- 1997-08-27 DE DE69733655T patent/DE69733655T2/de not_active Expired - Fee Related
- 1997-08-27 AU AU42387/97A patent/AU741199B2/en not_active Ceased
- 1997-08-27 CA CA002262453A patent/CA2262453A1/en not_active Abandoned
2000
- 2000-01-20 HK HK00100377A patent/HK1021741A1/xx not_active IP Right Cessation

Also Published As

Publication number	Publication date
PT929574E (pt)	2005-11-30
AU4238797A (en)	1998-03-19
AU741199B2 (en)	2001-11-22
CA2262453A1 (en)	1998-03-05
HK1021741A1 (en)	2000-06-30
DE69733655T2 (de)	2006-04-27
EP1586584A1 (de)	2005-10-19
EP0929574B1 (de)	2005-06-29
WO1998008868A1 (en)	1998-03-05
ES2245003T3 (es)	2005-12-16
DK0929574T3 (da)	2005-10-31
EP0929574A1 (de)	1999-07-21
DE69733655D1 (de)	2005-08-04
JP2001500852A (ja)	2001-01-23

Publication	Publication Date	Title
DE69733655D1 (de)	2005-08-04	beta-AMYLOID PEPTIDAGGREGATION REGULIERENDE PEPTIDE MIT D-AMINOSÄUREN
CY1106899T1 (el)	2012-09-26	Διαμορφωτες συσσωματωσης βητα-αμυλοειδων πεπτιδιων που περιλαμβανουν d-αμινοξεα
DE69713112D1 (de)	2002-07-11	Zusammensetzungen und methoden zur behandlung von infektionen unter verwendung von indolicidin-analogen
ATE168719T1 (de)	1998-08-15	Osteogene peptide
DK0792287T3 (da)	2004-08-30	Peptidanaloger af humant basisk myelinprotein
ATE417925T1 (de)	2009-01-15	Verfahren zur präsentation von (poly)peptiden/proteinen auf bakteriophagenpartikeln via disulfidbindungen
NO920671L (no)	1992-08-24	Fremgangsmaate for aktivering av rekombinante proteiner
ATE14226T1 (de)	1985-07-15	Cyclische octapeptide und pharmazeutische praeparate davon, sowie verfahren zur herstellung derselben und ihre anwendung.
DK0506748T3 (da)	1996-01-22	Aminosyrer, peptider eller derivater deraf bundet til fedtstoffer
DE69315730D1 (de)	1998-01-29	Verfahren zur Herstellung von Peptiden und neue Zwischenverbindungen dazu
ATE86260T1 (de)	1993-03-15	Peptid-molekuele, wirksam gegen gram-positive keime.
DE59108261D1 (de)	1996-11-14	Peptide des HIV-gag Proteins, ihre Herstellung und Verwendung
DE69613086D1 (de)	2001-07-05	Antigenen Peptide mit Glycinsubstitution
AU1464488A (en)	1988-10-20	Human rhinovirus peptides
IE881710L (en)	1988-12-09	(2-Cyano-2-oximinoacetyl)-amino acid derivatives
EP1870419A3 (de)	2008-01-02	Modulatoren der Beta-Amyloid-Peptid-Aggregation mit D-Aminosäuren

Legal Events

Date	Code	Title	Description
2006-05-15	UEP	Publication of translation of european patent specification	Ref document number: 0929574 Country of ref document: EP
2010-05-15	REN	Ceased due to non-payment of the annual fee

Date

Code

Title

Description

2006-05-15

UEP

Publication of translation of european patent specification

Ref document number: 0929574

Country of ref document: EP

2010-05-15

REN

Ceased due to non-payment of the annual fee